A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

NCT04641247 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Neoplasms
Breast Neoplasms

Interventions

DRUG: Niraparib

Sponsor

GlaxoSmithKline